Assets, Current in USD of Autolus Therapeutics plc from Q3 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
Summary
Autolus Therapeutics plc quarterly Assets, Current history and change rate from Q3 2017 to Q3 2025.
  • Autolus Therapeutics plc Assets, Current for the quarter ending 30 Sep 2025 was $515M, a 28.3% decline year-over-year.
Assets, Current, Quarterly (USD)
Assets, Current, YoY Quarterly Change (%)

Autolus Therapeutics plc Quarterly Assets, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $515M -$204M -28.3% 30 Sep 2025 10-Q 12 Nov 2025
Q2 2025 $574M -$184M -24.3% 30 Jun 2025 10-Q 12 Aug 2025
Q1 2025 $616M -$189M -23.4% 31 Mar 2025 10-Q 08 May 2025
Q4 2024 $661M +$386M +140% 31 Dec 2024 10-Q 12 Nov 2025
Q3 2024 $718M +$410M +133% 30 Sep 2024 10-Q 12 Nov 2024
Q2 2024 $759M +$403M +113% 30 Jun 2024 10-Q 08 Aug 2024
Q1 2024 $804M +$410M +104% 31 Mar 2024 10-Q 17 May 2024
Q4 2023 $275M -$150M -35.3% 31 Dec 2023 10-K 20 Mar 2025
Q3 2023 $308M +$96.1M +45.3% 30 Sep 2023 10-K 21 Mar 2024
Q2 2023 $355M +$96.4M +37.2% 30 Jun 2023 10-K 21 Mar 2024
Q1 2023 $394M +$84.4M +27.3% 31 Mar 2023 10-K 21 Mar 2024
Q4 2022 $426M +$78.8M +22.7% 31 Dec 2022 10-K 21 Mar 2024
Q3 2022 $212M 30 Sep 2022 10-K 21 Mar 2024
Q2 2022 $259M 30 Jun 2022 10-K 21 Mar 2024
Q1 2022 $309M +$21.4M +7.43% 31 Mar 2022 10-K 21 Mar 2024
Q4 2021 $347M +$150M +76.1% 31 Dec 2021 20-F 07 Mar 2023
Q1 2021 $288M +$7.12M +2.53% 31 Mar 2021 6-K 06 May 2021
Q4 2020 $197M -$52.3M -21% 31 Dec 2020 20-F 10 Mar 2022
Q3 2020 $229M -$31.3M -12% 30 Sep 2020 6-K 05 Nov 2020
Q2 2020 $249M -$44M -15% 30 Jun 2020 6-K 06 Aug 2020
Q1 2020 $281M 31 Mar 2020 6-K 07 May 2020
Q4 2019 $249M +$16.3M +6.99% 31 Dec 2019 20-F 04 Mar 2021
Q3 2019 $260M +$905K +0.35% 30 Sep 2019 6-K 07 Nov 2019
Q2 2019 $293M 30 Jun 2019 6-K 08 Aug 2019
Q4 2018 $233M 31 Dec 2018 20-F 03 Mar 2020
Q3 2018 $259M +$117M +82% 30 Sep 2018 20-F 25 Feb 2019
Q3 2017 $142M 30 Sep 2017 20-F 25 Feb 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.